Navigation Links
Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Date:3/2/2011

CHAPEL HILL, N.C., March 2, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference at 1:30 p.m. EST, March 7, 2011, at The Boston Marriott Copley Place in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com. Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.flamm@russopartnersllc.comTony Russo, Ph.D.Russo Partners, LLC(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
3. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
4. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
7. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
8. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
9. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection took ... This inspection was conducted as part of a routine Bioresearch Monitoring Program (BIMO) ...
(Date:8/15/2017)... Charlotte, NC (PRWEB) , ... August 15, 2017 , ... ... in 2017, celebrating 10 years of successes helping medical technology companies and inventors develop ... company to a renowned full-service national engineering firm with a portfolio of clients in ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... of 6” modular downlights designed to stay tightly sealed and perform efficiently for ... damp and wet location listings just aren't enough, such as: hospitals; behavioral health ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... performing antibodies. Key researchers in the antibody community have recently come together to ... for antibodies in the laboratory. , The team at Thermo ...
Breaking Biology Technology:
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):